Evgen Pharma (EVG)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

4.48p
   
  • Change Today:
    -0.070p
  • 52 Week High: 7.10
  • 52 Week Low: 2.85
  • Currency: UK Pounds
  • Shares Issued: 274.89m
  • Volume: 162,912
  • Market Cap: 12.31m
  • RiskGrade: 304

Evgen Pharma Overview

Evgen is a clinical stage drug development company focused on the development of sulforaphane-based compounds, a new class of pharmaceuticals which are synthesised in a proprietary, well-tolerated, stable formulation.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn n/a -780.0%
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue n/a 25.0
Pr/Book 1.4  
Latest F'cast
Revenue n/a n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

Evgen Pharma Fundamentals

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
31-Mar-18 n/a (3.03) (3.23)p n/a n/a n/a n/a 0.0%
31-Mar-19 n/a (3.12) (2.70)p n/a n/a n/a n/a 0.0%
31-Mar-20 n/a (3.17) (2.07)p n/a n/a n/a n/a 0.0%
31-Mar-21 0.19 (3.21) (1.82)p n/a n/a n/a n/a 0.0%
31-Mar-22 n/a (3.17) (0.99)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Evgen Pharma Forecasts

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
31-Mar-23 0.50 (3.90) (1.20)p n/a n/a n/a n/a 0.0%
31-Mar-24 5.00 (1.60) (0.20)p n/a n/a n/a n/a 0.0%

Copyright © 2023 FactSet Research Systems Inc. All rights reserved.

Evgen Pharma Company Announcements

Clinical trial update 25-Jan-2023 07:00 RNS
Grant of Options - Director/PDMR Shareholding 14-Dec-2022 17:08 RNS
Half-year Report 08-Dec-2022 07:00 RNS

Latest Evgen Pharma Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

Evgen Pharma Market Data

Currency UK Pounds
Share Price 4.48p
Change Today -0.070p
% Change -1.54 %
52 Week High 7.10
52 Week Low 2.85
Volume 162,912
Shares Issued 274.89m
Market Cap 12.31m
RiskGrade 304

Evgen Pharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
12.35% below the market average12.35% below the market average12.35% below the market average12.35% below the market average12.35% below the market average
51.72% above the sector average51.72% above the sector average51.72% above the sector average51.72% above the sector average51.72% above the sector average
Price Trend
12.94% above the market average12.94% above the market average12.94% above the market average12.94% above the market average12.94% above the market average
48.39% above the sector average48.39% above the sector average48.39% above the sector average48.39% above the sector average48.39% above the sector average
Income Not Available
Growth Not Available

Evgen Pharma Dividends

No dividends found

Trades for 06-Feb-2023

Time Volume / Share Price
08:32 50,000 @ 4.55p
08:28 212 @ 4.70p
08:28 100 @ 4.30p
08:27 2,600 @ 4.40p
08:24 50,000 @ 4.43p

Evgen Pharma Key Personnel

CFO Richard Moulson
CEO Huw Jones

Top of Page